Physician
Kaul, Karen
Kaul, Karen was paid $1.69M by Medicaid between Jan 2018 and Dec 2024, across 76 billing codes. Its largest line is 87491, Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe — 15% of everything it billed.
33Billing provider infoKAUL, KAREN
EVANSTON, IL 60201
EVANSTON, IL 60201
33aNPI1366483182assigned 06/10/2006
33bProvider typeAnatomic Pathology & Clinical Pathology Physician
28Total paid$1.69M
24GClaims176,845
24DCodes billed76
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Anatomic Pathology & Clinical Pathology Physician providers in Illinois
Rank by total paid#47 of 398
Median peer was paid$66K
This provider vs. median26×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 9,373 | $131K | |
| 2019 | 11,392 | $160K | |
| 2020 | 10,364 | $103K | |
| 2021 | 13,751 | $125K | |
| 2022 | 23,818 | $254K | |
| 2023 | 54,802 | $483K | |
| 2024incomplete | 53,345 | $438K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 15% | 11,475 | 10,960 | $253K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 15% | 11,378 | 10,915 | $251K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 7.3% | 721 | 653 | $123K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 7.2% | 24,072 | 22,127 | $123K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 6.8% | 4,531 | 4,050 | $115K |
| 87040 | 5.8% | 10,154 | 7,390 | $99K | |
| 87081 | 3.8% | 22,075 | 20,392 | $65K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 3.2% | 3,735 | 3,708 | $55K |
| 86235 | 2.8% | 1,206 | 1,138 | $47K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 2.7% | 5,052 | 4,823 | $45K |
| 87640 | 2.6% | 1,882 | 1,805 | $44K | |
| 87088 | 1.7% | 5,105 | 4,858 | $29K |
64 more codes
| 87075 | 1.6% | 4,137 | $28K | |
| 86780 | 1.5% | 3,079 | $26K | |
| 84702 | 1.4% | 5,219 | $24K | |
| 82784 | 1.2% | 2,393 | $20K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 1.2% | 2,195 | $20K |
| 87340 | 1.1% | 2,814 | $18K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 1.0% | 2,339 | $17K |
| 83516 | <1% | 3,160 | $16K | |
| 87496 | <1% | 712 | $16K | |
| 84466 | <1% | 2,985 | $13K | |
| 87205 | <1% | 6,746 | $13K | |
| 87481 | <1% | 1,838 | $13K | |
| 84153 | <1% | 1,715 | $11K | |
| 86225 | <1% | 1,866 | $11K | |
| 80074 | <1% | 569 | $11K | |
| 86803 | <1% | 1,330 | $11K | |
| 83883 | <1% | 1,081 | $11K | |
| 87070 | <1% | 3,157 | $10K | |
| 86706 | <1% | 1,404 | $9K | |
| 80202 | <1% | 1,357 | $9K | |
| 83520 | <1% | 1,321 | $8K | |
| 87505 | <1% | 866 | $8K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 737 | $7K |
| 82378 | <1% | 951 | $6K | |
| 87116 | <1% | 888 | $6K | |
| 82043 | <1% | 2,921 | $6K | |
| 82105 | <1% | 644 | $5K | |
| 86160 | <1% | 637 | $5K | |
| 86147 | <1% | 258 | $5K | |
| 87338 | <1% | 530 | $4K | |
| 86376 | <1% | 898 | $4K | |
| 86787 | <1% | 573 | $4K | |
| 87102 | <1% | 1,051 | $4K | |
| 86038 | <1% | 521 | $4K | |
| 81025 | <1% | 1,762 | $4K | |
| 86300 | <1% | 321 | $3K | |
| 87206 | <1% | 1,029 | $3K | |
| 86200 | <1% | 622 | $3K | |
| 83010 | <1% | 727 | $3K | |
| 86593 | <1% | 1,584 | $3K | |
| 86704 | <1% | 427 | $3K | |
| 87536 | <1% | 66 | $3K | |
| 87430 | <1% | 354 | $3K | |
| 87077 | <1% | 1,019 | $3K | |
| 87631 | <1% | 52 | $3K | |
| 87522 | Neg quan hep c or qual rna | <1% | 104 | $3K |
| 86765 | <1% | 484 | $2K | |
| 84154 | <1% | 308 | $2K | |
| 87210 | <1% | 862 | $2K | |
| 82274 | <1% | 393 | $2K | |
| 86431 | <1% | 546 | $2K | |
| 87517 | <1% | 205 | $2K | |
| 87177 | <1% | 491 | $2K | |
| 87493 | <1% | 80 | $2K | |
| 86304 | <1% | 143 | $2K | |
| 86316 | <1% | 188 | $1K | |
| 86301 | <1% | 113 | $1K | |
| 84165 | <1% | 135 | $941.29 | |
| 87046 | <1% | 317 | $806.28 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 68 | $612.00 |
| 86762 | <1% | 129 | $554.00 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 12 | $254.42 |
| 86645 | <1% | 13 | $108.27 | |
| 87045 | <1% | 13 | $78.90 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.